Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Trials ; 22(1): 762, 2021 Nov 02.
Article in English | MEDLINE | ID: mdl-34727951

ABSTRACT

BACKGROUND: It is a constant debate among surgeons whether the use of prolonged postoperative antibiotics may reduce surgical site infection rates. As specific treatment guidelines are still lacking, many surgeons continue to use broad-spectrum antibiotics, causing not only increased costs but also contributing to the potential for antibiotic resistance. Hence, there is an urgent need for an appropriately designed prospective clinical trial, to investigate whether a prophylactic use of antibiotics after surgery actually decreases surgical site infections to a clinically relevant degree. METHODS: This study presents a multicentre, randomised, controlled, double-blinded, clinical trial with two parallel study arms to demonstrate that no postoperative antibiotic prophylaxis (AP) is not inferior to antibiotic prophylaxis with respect to surgical site infections in patients having undergone orthognathic surgery. The primary efficacy endpoint is defined as the occurrence of postoperative surgical site infections within 30 days of surgery. Secondary endpoints are further efficacy and subject-oriented parameters within 90 days after surgery. The entire trial is planned for 54 months, with an enrolment of 1420 patients over 39 months by 14 national participating centres. DISCUSSION: As a highly standardised procedure on an exceeding, healthy and young homogenous study population and identical processes all over the world, elective orthognathic surgery as clean-contaminated procedure provides comparable intervention groups with balanced baseline characteristics, comparable surgical duration, even when performed within multiple centres. Therefore, evaluating antibiotic prophylaxis after orthognathic surgery will be of high scientific value representable for other surgical procedures. TRIAL REGISTRATION: DRKS-German Clinical Trials Register- DRKS00022838 ; EudraCT No. 2020-001397-30. Registered on 29 March 2021.


Subject(s)
Antibiotic Prophylaxis , Orthognathic Surgery , Anti-Bacterial Agents/adverse effects , Humans , Multicenter Studies as Topic , Prospective Studies , Randomized Controlled Trials as Topic , Surgical Wound Infection/diagnosis , Surgical Wound Infection/etiology , Surgical Wound Infection/prevention & control
2.
Mol Cell Endocrinol ; 342(1-2): 8-19, 2011 Aug 06.
Article in English | MEDLINE | ID: mdl-21672609

ABSTRACT

Kisspeptin, the product of the KiSS1 gene, has emerged as a key component of the mechanism by which the hypothalamus controls puberty and reproductive development. It does so by stimulating the secretion of gonadotropin releasing hormone (GnRH). Little is known about the transcriptional control of the KiSS1 gene. Here we show that a set of proteins postulated to be upstream components of a hypothalamic network involved in controlling female puberty regulates KiSS1 transcriptional activity. Using RACE-PCR we determined that transcription of KiSS1 mRNA is initiated at a single transcription start site (TSS) located 153-156bp upstream of the ATG translation initiation codon. Promoter assays performed using 293 MSR cells showed that the KiSS1 promoter is activated by TTF1 and CUX1-p200, and repressed by EAP1, YY1, and CUX1-p110. EAP1 and CUX-110 were also repressive in GT1-7 cells. All four TFs are recruited in vivo to the KiSS1 promoter and are expressed in kisspeptin neurons. These results suggest that expression of the KiSS1 gene is regulated by trans-activators and repressors involved in the system-wide control of mammalian puberty.


Subject(s)
Gene Expression Regulation , Kisspeptins/genetics , Transcription, Genetic , Chromatin Immunoprecipitation , Female , HeLa Cells , Humans , Hypothalamus/metabolism , Promoter Regions, Genetic/genetics , Puberty/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Trans-Activators/metabolism , Transcription Initiation Site
3.
J Neurosci ; 26(51): 13167-79, 2006 Dec 20.
Article in English | MEDLINE | ID: mdl-17182767

ABSTRACT

Thyroid transcription factor 1 (TTF1) [also known as Nkx2.1 (related to the NK-2 class of homeobox genes) and T/ebp (thyroid-specific enhancer-binding protein)], a homeodomain gene required for basal forebrain morphogenesis, remains expressed in the hypothalamus after birth, suggesting a role in neuroendocrine function. Here, we show an involvement of TTF1 in the control of mammalian puberty and adult reproductive function. Gene expression profiling of the nonhuman primate hypothalamus revealed that TTF1 expression increases at puberty. Mice in which the Ttf1 gene was ablated from differentiated neurons grew normally and had normal basal ganglia/hypothalamic morphology but exhibited delayed puberty, reduced reproductive capacity, and a short reproductive span. These defects were associated with reduced hypothalamic expression of genes required for sexual development and deregulation of a gene involved in restraining puberty. No extrapyramidal impairments associated with basal ganglia dysfunction were apparent. Thus, although TTF1 appears to fulfill only a morphogenic function in the ventral telencephalon, once this function is satisfied in the hypothalamus, TTF1 remains active as part of the transcriptional machinery controlling female sexual development.


Subject(s)
Basal Ganglia/physiology , Cell Differentiation/genetics , Gene Deletion , Neurons/cytology , Nuclear Proteins/biosynthesis , Nuclear Proteins/genetics , Reproduction/genetics , Transcription Factors/biosynthesis , Transcription Factors/genetics , Animals , Basal Ganglia/cytology , Female , Gene Expression Regulation, Developmental/physiology , Humans , Hypothalamus/cytology , Hypothalamus/physiology , Macaca mulatta , Male , Mice , Mice, Knockout , Mice, Transgenic , Neurons/physiology , Nuclear Proteins/deficiency , Sexual Behavior, Animal/physiology , Thyroid Nuclear Factor 1 , Transcription Factors/deficiency
SELECTION OF CITATIONS
SEARCH DETAIL
...